In the remaining two human studies on FDG uptake, Ripa et al. conducted an RCT of 51 patients with T2DM of 10–12 years duration vs. 51 placebo-treated patients; they found that the insulin releasing drug liraglutide, administered at 1.8 mg/d for 26 weeks, had virtually no effect on FDG uptake in the carotids and ascending aorta, albeit an exploratory analysis suggested a borderline significant effect in individuals with a history of CVD [46]. The gene discussed is INS; the disease is type 2 diabetes mellitus.